Guard Therapeutics International AB (publ)
GUARD.ST
Stockholm Stock Exchange1.40
SEK
-0.19
- -
Guard Therapeutics International AB (publ)
GUARD.ST
(Stockholm Stock Exchange)
Recent
price
1.40
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Guard Therapeutics International AB (publ) is a Swedish clinical-stage biotechnology company specializing in the identification and development of novel therapies for diseases with significant unmet medical needs, primarily focusing on kidney disease. The company’s core products include its clinical drug candidate RMC-035, developed as a kidney-protective treatment to prevent kidney injury during open-heart surgery and kidney transplantation, with sepsis as another potential indication. In addition, Guard Therapeutics develops a preclinical drug platform of A1M-like peptides known as GTX peptides, designed primarily for chronic kidney disease and administered via subcutaneous injection, enabling chronic self-treatment. The company also works on treatments related to autoimmune diseases and stroke based on the endogenous protein alpha-1-microglobulin (A1M). Guard Therapeutics operates in the biotechnology and pharmaceuticals sectors, focusing on therapeutic drug development within acute and chronic kidney disease and other related conditions such as preeclampsia. The company’s products and research activities are primarily centered in Sweden, with headquarters in Stockholm. Founded in 2008, Guard Therapeutics is publicly listed on Nasdaq First North Growth Market Stockholm under the ticker GUARD.ST. The company was formerly known as A1M Pharma AB until its name change in 2019. Its RMC-035 candidate is currently in phase 2b clinical trials, with a validated proof of concept, targeting hospital patients at risk of kidney injury. Recent major developments include a SEK 150 million rights issue completed in 2025, which provides funding to finalize the phase 2b POINTER study with expected readouts around the turn of the year and supports preparatory activities for the upcoming phase 3 trial. This funding bolsters the company’s clinical development and commercialization strategy for RMC-035. Guard Therapeutics continues to advance its GTX peptide platform and expand its research pipeline. The company emphasizes leveraging its expertise in alpha-1-microglobulin-based therapies to address serious kidney-related diseases and other conditions with high unmet needs. Guard Therapeutics maintains a small, highly specialized team with expertise in science, medicine, and drug development. Its research collaborations include partnerships with academic institutions such as Lund University. The company targets healthcare providers and hospitals as its primary customer base, focusing on treatments given in clinical settings to protect and repair kidney function and potentially other organ systems impacted by oxidative stress and tissue damage. In summary, Guard Therapeutics International AB develops innovative, alpha-1-microglobulin-based drugs with a leading product pipeline addressing acute kidney injuries and chronic kidney diseases, supported by recent financing initiatives to advance late-stage clinical trials and expand its technology platform, operating mainly in Sweden from its Stockholm headquarters since its founding in 2008.